John Pribis
Founder of Solu Therapeutics
Brookline, Massachusetts
Overview
Work Experience
Co-founder, Head of Business Strategy
2024 - Current
Co-founder and Head of BD, Strategy, and Operations
2023 - 2024
Founding VP of Strategy and Operations
2022 - 2023
Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
Raised $31,000,000.00 from Longwood Fund, Astellas Venture Management, Sante Ventures, Alexandria Venture Investments and DCVC Bio.
Senior Associate
2021 - 2023
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Co-founder, VP Strategy & Operations
2021 - 2022
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
Raised $70,000,000.00 from Emerson Collective, UTokyo Innovation Platform, Pfizer Venture Investments, Astellas Venture Management, Alta Partners, Alexandria Venture Investments, Longwood Fund and Insight Partners.
Co-founder, FL77, Inc (Apriori Bio)
2020 - 2021
Associate
2019 - 2021
Flagship Venture Fellow
2019 - 2019
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Graduate Student
2013 - 2019
Mechanisms of Antibiotic Resistance and Bacterial Evolvability
Director of Tri-Institutional Drug Discovery Program & Research Fellow
2008 - 2013
Team leader of a tri-institutional drug discovery program that led to the discovery of several drugs to treat sterile inflammation. Inflammation, traumatic injury, and susceptibility to infection after injury.